Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:25:36.950Z.
Calculation as of: 2026-10-06T18:25:36.950Z.
Quote observation: 2026-10-06T18:25:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 533c4696450707580a389d0c8167e09da333cd728c1767827588ef029f48caf5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$671.30M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$668.50M
Price/OCF Ratio
14.49
TTM Avg
11.83
3Y Avg
25.95
5Y Avg
25.95
Market Cap
$654.39M
Price/OCF Ratio
1995.09
TTM Avg
1890.32
3Y Avg
1890.32
5Y Avg
1890.32
Market Cap
$697.73M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $667.42M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $671.30M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.50M | 14.49 | 11.83 | 25.95 | 25.95 |
| Annexon, Inc. (ANNX)vs › | $670.12M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.64M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $684.87M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $654.39M | 1995.09 | 1890.32 | 1890.32 | 1890.32 |
| Verastem, Inc. (VSTM)vs › | $689.81M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $697.73M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $697.35M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
